Form 8-K - Current report:
SEC Accession No. 0001213900-25-062192
Filing Date
2025-07-09
Accepted
2025-07-09 08:00:52
Documents
13
Period of Report
2025-07-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0248347-8k_immucell.htm   iXBRL 8-K 27296
2 PRESS RELEASE OF IMMUCELL CORPORATION DATED JULY 9, 2025 ea024834701ex99-1_immucell.htm EX-99.1 24897
  Complete submission text file 0001213900-25-062192.txt   223506

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE iccc-20250709.xsd EX-101.SCH 3014
4 XBRL LABEL FILE iccc-20250709_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE iccc-20250709_pre.xml EX-101.PRE 22358
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0248347-8k_immucell_htm.xml XML 3558
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 251112300
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)